



PEPTECH
LIMITED

Peptech Limited
ABN 98 002 951 877

19-25 Khartoum Rd
Macquarie Park NSW 2113 Australia

Locked Bag 2053
North Ryde NSW 1670 Australia

Telephone +61 2 9870 8788
Facsimile +61 2 9870 8786

27 September 2006

ASX/MEDIA ANNOUNCEMENT

Peptech surpasses milestone in progress to market launch

Key messages

- **GMP material for PN0621 received**
- **Sufficient material for Phase I and II trials**
- **Yield significantly exceeded expectations**
- **Robust production process created**

Australian biotechnology company Peptech Limited (ASX: PTD) today announced it had passed a critical milestone on its path to commercialisation of the potential blockbuster drug, PN0621, by acknowledging the receipt of a substantial amount of the anti-TNF domain antibody (dAb)-based compound produced to the standards of Good Manufacturing Practice (GMP).

Peptech has received sufficient quantity of clinical grade PN0621 to advance further preclinical safety assessments and enable completion of Phase I and subsequently, Phase II human clinical trials.

The compound, to be trialled in multiple inflammatory diseases, has been produced to the exacting standards of GMP at industry-leading levels by an internationally reputed biopharmaceutical manufacturer. Levels of production and yield of purified material continue to exceed expectations.

Peptech Chief Executive Officer Dr John Chiplin said he was delighted with progress against a demanding schedule for clinical development of PN0621.

"PN0621 is Peptech's premium asset and leading compound. We are well justified in classifying this drug as a potential blockbuster, recognising the sales of anti-TNF products topped US\$8.7billion last year with less than twenty percent of the patient population currently accessing this type of medication," he said. "The market is far from saturated and growing rapidly – it is anticipated that it will exceed \$20 billion around the time of the market launch of PN0621."

"The receipt of the GMP-manufactured drug in these quantities enables us to complete the pre-clinical testing and key human clinical trials for rheumatoid arthritis and Crohn's disease indications, using a method endorsed by the major regulatory authorities. A crucial milestone for biologics is achieving cost-effective manufacture and the capacity to supply in line with market demand. It is therefore pleasing to see the manufacturing fundamentals for PN0621 looking this good."

"The international medical need for this compound is significant and the opportunity for registration for a number of indications is now firmly within our sights."

"We have focused heavily on safety, efficacy and manufacture of this product to ensure direct demonstration of benefits in the clinic together with cost competitive production, expected to significantly increase the product's commercial potential," Dr Chiplin said.

Phase I human clinical trials are on schedule to commence during the second quarter of 2007 with Phase II trials expected to start by the end of 2007.

Peptech has contracted a clinical trial centre for Phase I trials and is in the process of developing an Investigators Brochure and Phase I protocol documents.

ENDS

Further information:

Dr John Chiplin
Chief Executive Officer
Peptech Limited
Tel: + 61 2 9870 8788

Released by:

Ms Jodie Leckenby
Consultant
Phillips Group
Mobile: 0403 783 932

About Peptech:

Peptech Limited focuses on the research and development of peptides and proteins in the areas of human pharmaceuticals and animal health. The company is positioned to become a globally recognised leader in biopharmaceutical development.

For further information: www.peptech.com

About PN0621:

Peptech is confident that its lead anti-TNF dAb-based compound PN0621, used for the treatment of multiple inflammatory diseases, has two significant competitive advantages over current comparable products on the market.

Firstly, in preclinical trials the company found PN0621 to be more potent than a prominently marketed product and secondly, production data showed that the drug can be produced in large scaled-up quantities at an internationally competitive yield, with accompanying advantages in cost.